Investor Presentation First Nine Months of 2022
86
Investor presentation First nine months of 2022
While Norditropin® is the market leader within GHD market,
SogroyaⓇ represents an opportunity for patients
A portfolio offering across markets
Novo Nordisk leadership in competitive hGH market
DKK
billion
20
Value
MS%
Sogroya® launches
50%
15
10
5
40%
30%
20%
10%
0
0%
Jan
2019
Dec
2021
Segment Value
Novo Nordisk
Pfizer
Eli Lilly
Merck Kgaa
-Roche
hGH: Human growth hormone; SGA: Small for gestational age, ISS; Idiopathic short stature
Source: IQVIA, MAT Dec 2021; US panels for GHT has been removed from IQVIA from Jan 2022 version
SOGROYA®
somapacitan
norditropinⓇ
(somatropin) injection
•
Once-weekly efficacious treatment on par with NorditropinⓇ
Appears to have safe profile and no injection site reactions
Simple and easy-to-use device
Phase 3 trial towards broad range of indications (e.g. SGA,
Turner, Noonan, ISS) to expand the market
NorditropinⓇ strategy
.
Accompany markets slower to transition and specific
patient groups
Apply broad label across eight indications
Novo NordiskⓇView entire presentation